GSK, Theravance seek approvals for FF/VI in US, Europe
The companies also announced regulatory submission for FF/VI as asthma therapy in the European Union. FF/VI, which also includes the investigational LAMA/LABA combination umeclidinium bromide/vilanterol,VI monotherapy and MABA,